Macitentan tablets, 10 mg have an estimated market size of US $ 797 million for twelve months ending Dec 2021 according to IQVIA
The SMILE-100 System is a breast thermography device that helps healthcare personnel review, measure and analyze thermally significant indications in the breast region
The award recognizes and supports promising women scientists
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
It signals Cordis' renewed investment in innovation
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Use of Wipro Holmes Artificial Intelligence capabilities will lead to faster development of advanced therapeutics, improving patient outcomes
Tislelizumab is now approved for seven indications in China
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Subscribe To Our Newsletter & Stay Updated
